Grey Matters Health Inc.

Grey Matters Health Inc. is a Canadian healthcare company headquartered in Vancouver, British Columbia, primarily focused on establishing a national network of dedicated brain Positron Emission Tomography (PET) scanning clinics in the U.S.. The company's core mission is to address the growing need for early-stage detection of Alzheimer's Disease and other neurological conditions through advanced neuroimaging services.

The company's key services revolve around its NovaScan Neuroimaging Clinics™ brand, which provides brain-specific PET scanning for the early detection of Alzheimer's Disease, various forms of dementia, epilepsy, neuro-oncology, and movement disorders such as Parkinson's disease. These clinics utilize U.S. FDA-cleared, optimized brain-specific PET scanning systems, including the Oncovision CareMiBrain™ scanner, designed to detect amyloid plaques with lower radiation exposure than traditional methods. Additionally, Grey Matters Health is the parent company of Algernon NeuroScience, a wholly-owned subsidiary advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury recovery. The company also maintains a 20% equity position in Seyltx Inc., a private U.S. drug development company.

Effective April 21, 2026, the company officially changed its corporate name from Algernon Health Inc. to Grey Matters Health Inc., accompanied by a 10:1 share consolidation. Christopher J. Moreau serves as the Chief Executive Officer. Grey Matters Health is strategically repositioning itself around its NovaScan Neuroimaging Clinics™, with the first clinic slated to open in summer 2026 at the HCA Florida University Medical Office Building in Davie. The addressable market for these neuroimaging services is estimated at US$6.9 billion.